Living progression free means living
without your multiple myeloma getting worse. Trial 1:
At an average follow-up of 20.7 months, 74% (133 of 179 people) lived
progression free with sarclisa + Kyprolis® (carfilzomib) and
dexamethasone (Kd) vs 59% (73 of 123 people) treated with Kd alone.
Trial 2: At an average follow-up of 11.6 months, 53%
(81 of 154 people) lived progression free with SARCLISA + Pomalyst®
(pomalidomide) and dexamethasone (Pd) vs 42% (64 of 153 people) treated
with Pd alone.
Hear from people who are living with previously treated
multiple myeloma or caring for someone who is.
Our commitment to patients during COVID-19
Sanofi CareASSIST may be able to help address your financial assistance concerns
We understand that you may have concerns about paying for your treatment. If
you experience a change or loss in coverage, Sanofi CareASSIST may be able to help.
You can call 1-833-WE+CARE(1-833-930-2273), and a Patient Access
Specialist will review your specific eligibility during this time. Please click here.
To learn about the Sanofi response to COVID-19, please click here.
NOW FDA APPROVED A NEW TREATMENT OPTION
Read the official press release and talk
with your doctor to learn more.
This information is intended for US Healthcare Professionals only.
Select the “Continue” button below to go to the page you requested, or the “Cancel”
button to return to
the previous page.
You are about to leave SARCLISA.com.
Sanofi Genzyme does not review or control the content of non–Sanofi Genzyme
websites, and this hyperlink
does not constitute an endorsement by Sanofi Genzyme of the site's content. Sanofi
procedures do not apply to the owners of a non–Sanofi Genzyme website.
Sanofi US does not review the information
contained on this website and/or database
for content, accuracy or completeness. Use
of and access to this information is subject to
the terms, limitations and conditions set by the
website and/or database producer.
This site might not comply with the regulatory requirements of US